The stock of LAVA Therapeutics NV (NASDAQ: LVTX) has increased by 35.11 when compared to last closing price of 0.94. Despite this, the company has experienced a 38.03% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-10 that UTRECHT, The Netherlands and PHILADELPHIA, Jan. 10, 2025 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, announced dosing of the first patient in the Phase 1, first-in-human study of the CD123-targeted Gammabody®, LAVA-1266, an investigational agent in development for the treatment of hematologic cancers including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Is It Worth Investing in LAVA Therapeutics NV (NASDAQ: LVTX) Right Now?
LVTX has 36-month beta value of 0.56. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for LVTX is 13.02M, and currently, short sellers hold a 0.23% ratio of that float. The average trading volume of LVTX on February 25, 2025 was 104.01K shares.
LVTX’s Market Performance
The stock of LAVA Therapeutics NV (LVTX) has seen a 38.03% increase in the past week, with a 33.68% rise in the past month, and a -16.45% fall in the past quarter. The volatility ratio for the week is 3.23%, and the volatility levels for the past 30 days are at 4.90% for LVTX. The simple moving average for the past 20 days is 31.73% for LVTX’s stock, with a -25.16% simple moving average for the past 200 days.
Analysts’ Opinion of LVTX
Many brokerage firms have already submitted their reports for LVTX stocks, with Leerink Partners repeating the rating for LVTX by listing it as a “Market Perform.” The predicted price for LVTX in the upcoming period, according to Leerink Partners is $2 based on the research report published on December 12, 2024 of the previous year 2024.
H.C. Wainwright gave a rating of “Buy” to LVTX, setting the target price at $9 in the report published on October 25th of the previous year.
LVTX Trading at 27.98% from the 50-Day Moving Average
After a stumble in the market that brought LVTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.37% of loss for the given period.
Volatility was left at 4.90%, however, over the last 30 days, the volatility rate increased by 3.23%, as shares surge +36.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.28% lower at present.
During the last 5 trading sessions, LVTX rose by +43.46%, which changed the moving average for the period of 200-days by -56.00% in comparison to the 20-day moving average, which settled at $0.9666. In addition, LAVA Therapeutics NV saw 33.54% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for LVTX
Current profitability levels for the company are sitting at:
- -3.82 for the present operating margin
- 0.95 for the gross margin
The net margin for LAVA Therapeutics NV stands at -3.76. The total capital return value is set at -0.41. Equity return is now at value -63.12, with -28.44 for asset returns.
Based on LAVA Therapeutics NV (LVTX), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -4.49.
Currently, EBITDA for the company is -40.42 million with net debt to EBITDA at 0.76. When we switch over and look at the enterprise to sales, we see a ratio of 1.77. The receivables turnover for the company is 7.17for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.36.
Conclusion
To put it simply, LAVA Therapeutics NV (LVTX) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
